Drug intelligence / Profile preview

Uvax-2129

Development stage: Unknown
Lead developer: Uvax Bio
Modality: Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

Uvax-2129 is an investigational **recombinant protein nanoparticle vaccine** developed by **Uvax Bio** for prevention of **COVID-19**. It is built using the company\u2019s licensed **single component self-assembling protein nanoparticle 1c-SApNP technology** and is designed around the **SARS-CoV-2 spike protein** antigen. Preclinical reports described broad neutralizing antibody responses against the ancestral Wuhan strain and multiple variants including **alpha, beta, gamma, and delta**, supporting its use as a prophylactic antiviral vaccine candidate. A Phase 1 clinical trial was stated to be planned for the first half of 2022.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Uvax-2129.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uvax-2129.

Explore the full profile